Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.

About ABRAXANE (R)

The U.S. Food and Drug Administration approved ABRAXANE (R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... June 29, 2015 The Parenteral Drug Association ... Jersey Board of Professional Engineers and Land ... courses to professional engineers for continuing professional competency (CPC) ... the value and quality of PDA,s professional education offerings," ... courses and hands-on professional training at the Training and ...
(Date:6/29/2015)... June 29, 2015  Pressure BioSciences, Inc. (OTCQB: ... the development and sale of broadly enabling, pressure ... worldwide life sciences industry, today announced that Tiannan ... Systems Biology, ETH Zurich, presented data on an ... of prostate cancer tissue biopsy samples at the ...
Breaking Medicine Technology:Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 2Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 3Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 4
... Association rapid access journal report:Study highlights:-- Implantable ... of death by 30 percent in patients ... applied to patients 75 years and older ... have focused on younger, healthier patients.DALLAS, Jan. ...
... Corporation (Nasdaq: MNKD ) today announced ... its commercial inhaler to the version of the device ... MannKind,s ultra rapid acting insulin that recently completed Phase ... Clinical and Commercial Scale Inhalers Study 138 compared the ...
Cached Medicine Technology:Implantable Defibrillators Lower Risk of Death in Older Heart Patients 2Implantable Defibrillators Lower Risk of Death in Older Heart Patients 3MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
(Date:6/29/2015)... , ... June 29, 2015 , ... ... Medical Devices , **FDAnews Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 ... ensure the application of human factors engineering to the design of new products ...
(Date:6/29/2015)... New York, New York (PRWEB) , ... June ... ... transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against C.R. Bard, Inc. and ... According to court documents, the proceedings’ next Case Management Conference is to be ...
(Date:6/29/2015)... , ... June 29, 2015 , ... San Fernando ... lift and tighten sagging skin. Ulthera is a special treatment that offers a way ... ultrasound technology to gently stimulate collagen production. Ulthera is highly targeted and precise to ...
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has ... Bio to French consumers. , The specialized eye health formulation contains a variety ... free radicals. In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin ...
(Date:6/29/2015)... ... June 29, 2015 , ... Blue Cross ... leaders with the Commercial Markets division, which includes the company’s commercial health plan ... companies with regional, national and international reach. Mary Ellen Anderson now holds the ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3
... S.C., June 26 Southern Home Medical,Equipment, Inc. ... Medical Staffing of Greenville, S.C. has completed its ... shifts., Greg Tucker, President and CEO of ... doing extremely well. The Greenville team has far,exceeded ...
... June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced ... candidate in its Beta-catenin Pathway Inhibitor program. This novel compound ... cancer cell death. The Company plans to begin ... is one of the most commonly activated cancer pathways and ...
... La., June 26 Lee Pryor, CEO of ... courseware and,learning management solutions, announced Portico,s partnership with ... such as FOX,Sports, FOX Cable Networks, FOX Reality, ... a global initiative across all News Corporation businesses,FNG ...
... Demo Showcases That Yesterday,s FCC Mandate is Quick ... GoAmerica, Inc.,(Nasdaq: GOAM ), a provider of ... deaf, hard-of-hearing, and,speech-disabled persons, and AT&T today announced ... live point-to-point video call through a,10-digit numbering system ...
... The International Association for Dental Research (IADR) is ... Senior Lecturer in Periodontology at the School of Dental ... award will be presented at the IADR 86th General ... 2008., Dr. Preshaw holds a B.D.S. from Newcastle University, ...
... Dental Research (IADR) has selected Dr. Stuart Fischman, ... of Dental Medicine, at the State University of ... Pharmacology/Therapeutics/Toxicology Research Award. The award will be presented ... Toronto, ON, Canada on July 2, 2008., Dr. ...
Cached Medicine News:Health News:Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement 2Health News:Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program 2Health News:FOX Networks Group in Partnership with Portico Learning Solutions Launches Online Employee Health and Safety Orientation Course for Over 3,300 Employees 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 3Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 4Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 5Health News:Fischman receives Pharmacology/Therapeutics/Toxicology Research Award 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: